Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint

/PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Related Keywords

China ,Taiwan ,United States ,Peking ,Beijing ,Hong Kong ,Macau ,Suzhou ,Jiangsu ,Chinese ,Innovent Biologics ,Adimab Incyte ,Yong Huo ,Eli Lilly ,China Cardiovascular Health ,Md Anderson Cancer Center ,University First Hospital ,National Medical Products Administration ,Incyte Corporation ,Innovent Biologics Inc ,Drug Evaluation ,Peking University First Hospital ,Lei Qian ,Executive Director ,Three Registration Clinical Studies ,Total Cholesterol ,Cardiovascular Health ,Disease Report ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Mainland China ,